Alnylam Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –
Alnylam Pharmaceuticals Nasdaq Biotechnology Index Peer Group Cumulative TSR by Year
Nasdaq Biotechnology Index Peer Group Cumulative TSR Value of Initial $100 Investment ($) ($)
Alnylam Pharmaceuticals Nasdaq Biotechnology Index Peer Group Cumulative TSR: $125 in FY2025, up 33.4% from a year earlier.
Where the FY2025 figure comes from
“|| 2025 | 14,867,600 | 77,428,521 | 6,582,418 | 19,817,949 | 305.96 | 124.75 | 313,747 | 2,986,549”
Source: Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nasdaq Biotechnology Index Peer Group Cumulative TSR Value of Initial $100 Investment ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 125 | +33.4% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2024 | Dec 31, 2024 | 93.49 | -0.6% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2023 | Dec 31, 2023 | 94.03 | +4.6% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2022 | Dec 31, 2022 | 89.90 | -10.1% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2021 | Dec 31, 2021 | 100 | -20.9% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2020 | Dec 31, 2020 | 126 | – | Alnylam Form DEF 14A (2025 Proxy Statement (DEF 14A), filed 2025-03-24) ↗ |
Cite this data
StockData. (2026). Alnylam Pharmaceuticals Nasdaq Biotechnology Index Peer Group Cumulative TSR ($), annual FY2020–FY2025 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/proxy-peer-tsr-100
See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?